STING1
Stimulator of interferon genes protein
As of the edition of 20 October 2026, STING1 (stimulator of interferon genes protein, UniProt Q86WV6) has 10 drugs tested at it and 12 companies on the list, 8 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q86WV6
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 126
- Disease areas
- Cancer; Blood and lymph; Lungs and airways; Immune system; Urinary and reproductive; Pregnancy and women's health; Chemically induced; Injuries
- Registered trials of its drugs
- 35
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 6 |
| Status not established | 2 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vadimezan | Stopped | Phase 3 | none listed |
| IMSA101 | Active | Phase 2 | none listed |
| ADU-S100 | Stopped | Phase 2 | none listed |
| Dazostinag | Status not established | Phase 2 | none listed |
| E-7766 | Stopped | Phase 1 | none listed |
| GSK3745417 | Stopped | Phase 1 | none listed |
| BMS-986301 | Status not established | Phase 1 | none listed |
| ONM-501 | Active | Phase 1 | none listed |
| SNX281 | Stopped | Phase 1 | none listed |
| SYNB1891 | Stopped | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Engaged | 1 |
| Undetermined | 3 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| Novartis | Route A |
| ImmuneSensor Therapeutics | Route A |
| GSK | Route A |
The other 9 companies at STING1
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at STING1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.